Norway-based Targovax ASA has reported promising Phase 1 data for its oncolytic virus treatment ONCOS-102 in combination with pembrolizumab in patients with advanced, unresectable melanoma. The patients had experienced disease progression despite treatment with a checkpoint inhibitor, yet in the study tumour responses were observed in seven out of 20 evaluable patients.
